cycloartane has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akgün, İH; Bedir, E; Debeleç-Bütüner, B; Korkmaz, KS; Öztürk, MB; Tağ, Ö; Yetik-Anacak, G | 1 |
| Chen, Y; Dong, X; Gao, W; Su, X; Wei, T; Xin, P; Yu, C; Zhou, C | 1 |
2 other study(ies) available for cycloartane and Cancer of Prostate
| Article | Year |
|---|---|
Cycloartane-type sapogenol derivatives inhibit NFκB activation as chemopreventive strategy for inflammation-induced prostate carcinogenesis.
Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Chemoprevention; Dinoprostone; Humans; Inflammation; Male; NF-kappa B; Prostatic Neoplasms; Sapogenins; Signal Transduction; Transcription, Genetic; Triterpenes | 2018 |
Cycloartan-24-ene-1α,2α,3β-triol, a cycloartane-type triterpenoid from the resinous exudates of Commiphora myrrha, induces apoptosis in human prostatic cancer PC-3 cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Commiphora; Flow Cytometry; Humans; In Situ Nick-End Labeling; Male; Phytotherapy; Prostatic Neoplasms; Resins, Plant; Triterpenes | 2015 |